Clinical TrialJun 25, 2026, 08:09 AM
MAIA Biotechnology Completes International Enrollment for THIO-101 Part C
AI Summary
MAIA Biotechnology announced the completion of international enrollment for Part C of its Phase 2 THIO-101 expansion trial, evaluating ateganosine in advanced non-small cell lung cancer (NSCLC) patients. Forty-one patients were enrolled across six international sites, while domestic enrollment is now underway at three U.S. clinical sites. The company highlighted promising previous data from Parts A and B, showing a median survival of 17.8 months compared to an expected 5.8 months, and noted ateganosine's FDA Fast Track designation.
Key Highlights
- International enrollment for THIO-101 Part C completed across 6 countries.
- 41 patients enrolled and receiving treatment in international Part C sites.
- Domestic enrollment for THIO-101 Part C is underway at three U.S. clinical sites.
- Ateganosine is being evaluated for advanced NSCLC patients receiving third-line therapy.
- Parts A and B of THIO-101 showed median survival of 17.8 months.
- Expected survival in this heavily pre-treated population is 5.8 months.
- FDA granted Fast Track designation for ateganosine in NSCLC treatment.
Price Impact
More from MAIA